Novakand Pharma AB (publ) (LARK) — Working Capital to Net Assets Ratio
Novakand Pharma AB (publ) (LARK) has a Working Capital to Net Assets ratio of 11.7% as of June 2026. Working capital of Skr6.64 Million (current assets of Skr7.48 Million minus current liabilities of Skr846.00K) is measured against net assets of Skr56.71 Million. A higher ratio indicates strong short-term liquidity financed by the equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Novakand Pharma AB (publ) Working Capital to Net Assets (2012–2025)
This chart shows how Novakand Pharma AB (publ)'s Working Capital to Net Assets ratio has evolved across 14 annual periods from 2012 to 2025. As of June 2026, the ratio stands at 11.7%, reflecting working capital of Skr6.64 Million against net assets of Skr56.71 Million SEK. See how many days can Novakand Pharma AB (publ) fund operations to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Novakand Pharma AB (publ) (2012–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Novakand Pharma AB (publ) from 2012 to 2025, covering 14 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Novakand Pharma AB (publ) balance sheet assets.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 9.8% | Skr5.42 Million | Skr55.49 Million | Skr6.66 Million | Skr1.24 Million | ▼ -89.2 pp |
| 2024 | 98.9% | Skr70.82 Million | Skr71.58 Million | Skr75.12 Million | Skr4.30 Million | ▲ +13.9 pp |
| 2023 | 85.1% | Skr99.08 Million | Skr116.46 Million | Skr103.24 Million | Skr4.16 Million | ▼ -2.4 pp |
| 2022 | 87.5% | Skr133.12 Million | Skr152.12 Million | Skr139.22 Million | Skr6.10 Million | ▲ +1.2 pp |
| 2021 | 86.4% | Skr136.68 Million | Skr158.28 Million | Skr144.62 Million | Skr7.94 Million | ▲ +20.0 pp |
| 2020 | 66.3% | Skr47.39 Million | Skr71.43 Million | Skr55.37 Million | Skr7.98 Million | ▲ +89.1 pp |
| 2019 | -22.8% | Skr-4.63 Million | Skr20.30 Million | Skr18.88 Million | Skr23.51 Million | ▼ -114.7 pp |
| 2018 | 91.9% | Skr18.80 Million | Skr20.46 Million | Skr33.46 Million | Skr14.66 Million | ▲ +10.7 pp |
| 2017 | 81.2% | Skr5.29 Million | Skr6.51 Million | Skr6.92 Million | Skr1.63 Million | ▲ +11.2 pp |
| 2016 | 70.0% | Skr2.86 Million | Skr4.08 Million | Skr3.67 Million | Skr809.66K | ▼ -18.0 pp |
| 2015 | 88.0% | Skr9.04 Million | Skr10.27 Million | Skr9.73 Million | Skr691.73K | ▲ +3.0 pp |
| 2014 | 85.0% | Skr4.82 Million | Skr5.67 Million | Skr5.40 Million | Skr582.04K | ▲ +88.9 pp |
| 2013 | -3.8% | Skr-23.01K | Skr598.60K | Skr17.97K | Skr40.98K | ▲ +90.2 pp |
| 2012 | -94.0% | Skr-280.30K | Skr298.09K | Skr16.28K | Skr296.58K | — |